SIM 0237
Alternative Names: SIM-0237; SIM-237Latest Information Update: 02 Jan 2025
At a glance
- Originator Simcere Pharmaceutical Group
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Interleukins; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Interleukin 15 replacements; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bladder cancer; Solid tumours
Most Recent Events
- 17 Dec 2024 Jiangsu Simcere Pharmaceutical terminates Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China and the US (IV), due to an internal business decision, and not based on safety or regulatory considerations (NCT05781360)
- 23 Jan 2024 Phase-I clinical trials in Bladder cancer (Combination therapy) in China (Intravesicular) (NCT06186414)
- 23 Jan 2024 Phase-I clinical trials in Bladder cancer (Monotherapy) in China (Intravesicular) (NCT06186414)